ロード中...
Defining molecular risk in ALK(+) NSCLC
Anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancers (NSCLC) have the best prognosis among metastatic pulmonary malignancies, with a median patient survival currently exceeding 5 years. While this is definitely a major therapeutic success for thoracic oncology, it may not be entirel...
保存先:
| 出版年: | Oncotarget |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Impact Journals LLC
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6517105/ https://ncbi.nlm.nih.gov/pubmed/31139322 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.26886 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|